{
    "clinical_study": {
        "@rank": "149476", 
        "arm_group": {
            "arm_group_label": "single arm with Tremelimumab", 
            "arm_group_type": "Experimental", 
            "description": "Tremelimumab: 10mg/Kg ev day 1 every 4 weeks for 6 doses in induction phase, then every 12 weeks in maintenance phase until disease progression of severe toxicity"
        }, 
        "brief_summary": {
            "textblock": "RATIONAL: Preliminary results fron the Study MESOT-TREM-2012 indicate a promising activity\n      of tremelimumab in malignant mesothelioma (MM) patients.\n\n      PURPOSE: The proposed study MESOT-TREM-2012 aims to explore the efficacy of a more intensive\n      schedule of treatment with tremelimumab in 29 MM patients. Subjects will receive\n      investigational product every 4 weeks (wks) for 6 doses, followed by doses every 12 wks\n      until confirmed disease progression."
        }, 
        "brief_title": "The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Malignant Mesothelioma", 
        "condition_browse": {
            "mesh_term": "Mesothelioma"
        }, 
        "detailed_description": {
            "textblock": "Primary endpoint:\n\n      1) To assess the rate of objective clinical complete response (CR) or partial response (PR)\n\n      Secondary endpoints:\n\n        1. To define toxicity profile according to NCI CT-CAE V. 3\n\n        2. To assess the overall survival (OS)\n\n        3. To estimate disease control rate (DCR) (proportion of patients with best response of\n           CR+PR+SD) according to the modified Recist criteria\n\n        4. To assess the progression-free survival in treated patients according to modified\n           Recist criteria\n\n        5. To evaluate qualitative and quantitative changes in cellular and humoral immune\n           responses"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed MM\n\n          -  Have received only one prior systemic chemotherapy platinum-based regimen   for\n             advanced MM\n\n          -  Measurable disease, defined at least 1 unidimensionally measurable lesion > 20 mm by\n             conventional techniques or > 10 mm by spiral CT scan (modified RECIST criteria)\n\n          -  Disease not amenable to curative surgery\n\n          -  No known brain metastasis\n\n          -  Age 18 and over\n\n          -  Performance status 0-2\n\n          -  Life expectancy > 12 weeks\n\n          -  Adequate hematologic, hepatic and renal function\n\n          -  Platelet count > 75000/mm3\n\n          -  Absolute granulocyte count > 1000/mm3\n\n          -  Hemoglobin >  9 g/dL\n\n          -  Bilirubin total < 1.5 x ULN (Upper limited normal), except patients with documented\n             Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dl\n\n          -  AST and ALT < 2.5 x ULN ( < 5 x ULN if documented liver metastasis are present)\n\n          -  Creatinine level < 2mg/dl or calculated creatinine clearance > 60 mL/min as\n             determined by the Cockcroft Gault equation.\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n          -  Patient must be willing and able to provide written informed consent, and the trial\n             have to be approved by the institutional review board at each institution\n\n        Exclusion Criteria:\n\n          -  Symptomatic chronic inflammatory or autoimmune disease\n\n          -  Active hepatitis B or C\n\n          -  Prior treatment with tremelimumab or other anti-CTLA-4 antibody or anti-PD1,\n             anti-PDL-1 agents\n\n          -  Clinically relevant cardiovascular disease\n\n          -  History of psychiatric disabilities, potentially interfering with the capability of\n             giving adequate informed consent\n\n          -  Uncontrolled active infections\n\n          -  Other concurrent chemotherapy, immunotherapy, radiotherapy or investigational agents\n\n          -  History of other malignancies except for adequately treated basal cell carcinoma or\n             squamous cell skin cancer or carcinoma of cervix, unless the patient has been\n             disease-free for at least 5 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01655888", 
            "org_study_id": "MESOT-TREM-2012", 
            "secondary_id": "2012-002762-12"
        }, 
        "intervention": {
            "arm_group_label": "single arm with Tremelimumab", 
            "description": "Tremelimumab is administered as endovenous infusion", 
            "intervention_name": "Tremelimumab", 
            "intervention_type": "Drug", 
            "other_name": "CP-675,206"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Tremelimumab", 
            "anti-CTLA-4 monoclonal antibody", 
            "malignant mesothelioma"
        ], 
        "lastchanged_date": "July 31, 2012", 
        "location": {
            "contact": {
                "email": "mmaio@cro.it", 
                "last_name": "Michele Maio, MD", 
                "phone": "+39-0577586335"
            }, 
            "contact_backup": {
                "email": "l.calabro@ao-siena.toscana.it", 
                "last_name": "Luana Calabr\u00f2, MD", 
                "phone": "+39-0577586116"
            }, 
            "facility": {
                "address": {
                    "city": "Siena", 
                    "country": "Italy", 
                    "zip": "53100"
                }, 
                "name": "Medical Oncology and Immunotherapy Unit, University Hospital of Siena"
            }, 
            "investigator": [
                {
                    "last_name": "Michele Maio, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Luana Calabr\u00f2, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012", 
        "overall_contact": {
            "email": "mmaio@cro.it", 
            "last_name": "Michele Maio, MD", 
            "phone": "+39-0577586335"
        }, 
        "overall_contact_backup": {
            "email": "l.calabro@ao-siena.toscana.it", 
            "last_name": "Luana Calabr\u00f2, MD", 
            "phone": "+39-0577586116"
        }, 
        "overall_official": [
            {
                "affiliation": "Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Italy", 
                "last_name": "Michele Maio, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Medical Oncology and Immunotherapy, University Hospital of Siena, Italy", 
                "last_name": "Luana Calabr\u00f2, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The objective response is defined as a confirmed complete response (CR), or partial response (PR) according to the modified RECIST Criteria for pleural mesothelioma and the immune-related (ir) Response Criteria", 
            "measure": "To determine the objective response", 
            "safety_issue": "No", 
            "time_frame": "Weeks 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01655888"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Azienda Ospedaliera Universitaria Senese", 
            "investigator_full_name": "Michele Maio", 
            "investigator_title": "Head of Medical Oncology and Immunotherapy Unit", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "DCR is the proportion of treated subjects that achieved confirmed CR or PR  or stable disease (SD) The DCR is assessed using the modified RECIST Criteria for pleural mesothelioma umor assessment and the the immune-related response criteria", 
                "measure": "Disease control rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "The assessment of safety includes serious and non-serious adverse events according to NCI-CTC criteria version 3.0. In addition, laboratory evaluation, abnormal vital signs and physycal examination findings are also included.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Progression free survival is computed from the first day of study treatment to the day of documented progression according to the modified RECIST Criteria for pleural mesothelioma or death, whichever occurs first", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "1 years"
            }
        ], 
        "source": "Azienda Ospedaliera Universitaria Senese", 
        "sponsors": {
            "collaborator": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Azienda Ospedaliera Universitaria Senese", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}